P&G/Watson Macrobid "Authorized" Generic Launch Prompts Mylan Lawsuit
This article was originally published in The Pink Sheet Daily
Executive Summary
The practice of a branded company "authorizing" a generic misleads consumers and undercuts Waxman/Hatch incentives, Mylan says. Watson launched its generic one day after Mylan received ANDA approval and began marketing nitrofurantoin under 180 days of exclusivity.
You may also be interested in...
Mylan's Legal Fight Against "Authorized" Generics May Shift To Antitrust Attack
Generic firm dismisses lawsuit against FDA seeking a preliminary injunction related to Watson's marketing of a Macrobid "authorized" generic. Dismissal comes shortly before a W.Va. federal judge was expected to rule on claims under the FD&C Act and Administrative Procedures Act. Mylan could revive its lawsuit through antitrust claims.
Mylan's Legal Fight Against "Authorized" Generics May Shift To Antitrust Attack
Generic firm dismisses lawsuit against FDA seeking a preliminary injunction related to Watson's marketing of a Macrobid "authorized" generic. Dismissal comes shortly before a W.Va. federal judge was expected to rule on claims under the FD&C Act and Administrative Procedures Act. Mylan could revive its lawsuit through antitrust claims.
Mylan Sues FDA, Seeks Injunction Against Macrobid “Authorized” Generic
The lawsuit, filed in Clarksburg, W.Va. federal court, says authorized generic deals “deter competition by discouraging challenges to even the weakest patents.”